Relating drug–protein interaction network with drug side effects

Motivation: Identifying the emergence and underlying mechanisms of drug side effects is a challenging task in the drug development process. This underscores the importance of system–wide approaches for linking different scales of drug actions; namely drug-protein interactions (molecular scale) and side effects (phenotypic scale) toward side effect prediction for uncharacterized drugs. Results: We performed a large-scale analysis to extract correlated sets of targeted proteins and side effects, based on the co-occurrence of drugs in protein-binding profiles and side effect profiles, using sparse canonical correlation analysis. The analysis of 658 drugs with the two profiles for 1368 proteins and 1339 side effects led to the extraction of 80 correlated sets. Enrichment analyses using KEGG and Gene Ontology showed that most of the correlated sets were significantly enriched with proteins that are involved in the same biological pathways, even if their molecular functions are different. This allowed for a biologically relevant interpretation regarding the relationship between drug–targeted proteins and side effects. The extracted side effects can be regarded as possible phenotypic outcomes by drugs targeting the proteins that appear in the same correlated set. The proposed method is expected to be useful for predicting potential side effects of new drug candidate compounds based on their protein-binding profiles. Supplementary information: Datasets and all results are available at http://web.kuicr.kyoto-u.ac.jp/supp/smizutan/target-effect/. Availability: Software is available at the above supplementary website. Contact: yamanishi@bioreg.kyushu-u.ac.jp, or goto@kuicr.kyoto-u.ac.jp

[1]  Yoshihiro Yamanishi,et al.  Predicting drug side-effect profiles: a chemical fragment-based approach , 2011, BMC Bioinformatics.

[2]  Roded Sharan,et al.  An Algorithmic Framework for Predicting Side-Effects of Drugs , 2010, RECOMB.

[3]  A. Fliri,et al.  Analysis of System Structure–Function Relationships , 2007, ChemMedChem.

[4]  D. Bojanic,et al.  Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development. , 2005, Drug discovery today.

[5]  J. C. O'Keefe,et al.  Efficacy of nisoldipine combined with beta‐adrenergic‐blocking drugs in the treatment of chronic stable angina , 1987, Clinical cardiology.

[6]  B. Law,et al.  Rapamycin: an anti-cancer immunosuppressant? , 2005, Critical reviews in oncology/hematology.

[7]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[8]  S Giménez-Roldán,et al.  Cinnarizine-induced parkinsonism. Susceptibility related to aging and essential tremor. , 1991, Clinical neuropharmacology.

[9]  W. Foye,et al.  Foye's Principles of Medicinal Chemistry , 2002 .

[10]  Robert B. Russell,et al.  SuperTarget and Matador: resources for exploring drug-target relationships , 2007, Nucleic Acids Res..

[11]  P. Bork,et al.  A side effect resource to capture phenotypic effects of drugs , 2010, Molecular systems biology.

[12]  Chantal Dessy,et al.  A role for MAP kinase in differentiated smooth muscle contraction evoked by α-adrenoceptor stimulation. , 1998, American journal of physiology. Cell physiology.

[13]  Navdeep Jaitly,et al.  A Structure-Based Approach for Mapping Adverse Drug Reactions to the Perturbation of Underlying Biological Pathways , 2010, PloS one.

[14]  A. Bender,et al.  Analysis of Pharmacology Data and the Prediction of Adverse Drug Reactions and Off‐Target Effects from Chemical Structure , 2007, ChemMedChem.

[15]  Susumu Goto,et al.  KEGG for representation and analysis of molecular networks involving diseases and drugs , 2009, Nucleic Acids Res..

[16]  Philip E. Bourne,et al.  Drug Discovery Using Chemical Systems Biology: Identification of the Protein-Ligand Binding Network To Explain the Side Effects of CETP Inhibitors , 2009, PLoS Comput. Biol..

[17]  Fahmeed Hyder,et al.  Effects of Gabapentin on Brain GABA, Homocarnosine, and Pyrrolidinone in Epilepsy Patients , 2000, Epilepsia.

[18]  I. Rogatsky,et al.  Minireview: Glucocorticoids in autoimmunity: unexpected targets and mechanisms. , 2011, Molecular endocrinology.

[19]  M. Milik,et al.  Mapping adverse drug reactions in chemical space. , 2009, Journal of medicinal chemistry.

[20]  C. Gordon,et al.  The effects of dimenhydrinate, cinnarizine and transdermal scopolamine on performance , 2001, Journal of psychopharmacology.

[21]  Yoshihiro Yamanishi,et al.  Drug-target interaction prediction from chemical, genomic and pharmacological data in an integrated framework , 2010, Bioinform..

[22]  R. Tibshirani,et al.  A penalized matrix decomposition, with applications to sparse principal components and canonical correlation analysis. , 2009, Biostatistics.

[23]  A. Fliri,et al.  Analysis of drug-induced effect patterns to link structure and side effects of medicines , 2005, Nature chemical biology.

[24]  John Sharkey,et al.  Acquired QT interval prolongation and HERG: implications for drug discovery and development. , 2004, European journal of pharmacology.

[25]  David S. Wishart,et al.  DrugBank: a knowledgebase for drugs, drug actions and drug targets , 2007, Nucleic Acids Res..

[26]  R. Altman,et al.  Predicting drug side-effects by chemical systems biology , 2009, Genome Biology.

[27]  P. Bork,et al.  Drug Target Identification Using Side-Effect Similarity , 2008, Science.

[28]  G. Rouan,et al.  Acute Methemoglobinemia Secondary to Topical Benzocaine Spray , 2003 .

[29]  S. Bryant,et al.  PubChem as a public resource for drug discovery. , 2010, Drug discovery today.

[30]  M. Ashburner,et al.  Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.

[31]  O. Geyer,et al.  Ophthalmic complications of dental anesthesia: three new cases. , 2005, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.